Material Safety Data Sheet
Section 1. Chemical Product and Company Identification
Product Name MAGNACIDE® B MICROBIOCIDE Code XCB
Supplier Baker Petrolite Version 8.0
A Baker Hughes Company
12645 W. Airport Blvd. (77478)
P.O. Box 5050
Sugar Land, TX 77487-5050
For Product Information/MSDSs: 800-231-3606,
(001)281-276-5400
Material Uses Microbiocide Effective Date 01/08/2007
24 Hour CHEMTREC 800-424-9300 Print Date 01/08/2007
Emergency Baker Petrolite 800-231-3606, (001)281-276-5400
Numbers CANUTEC 613-996-6666
CHEMTREC Int’l 01-703-527-3887 (International)
National Fire Protection
Association (U.S.A.)
Section 2. Composition and Information on Ingredients
Name CAS # % by Weight Exposure Limits
Acrolein 107-02-8 95 ACGIH (United States). Skin
CEIL: 0.1 ppm
OSHA (United States).
TWA: 0.1 ppm
TWA: 0.25 mg/m3
The OSHA STEL of 0.3 ppm was vacated by Court order, but is still in effect in AK, CA, MI, MN, NC, TN and
WA.
Section 3. Hazards Identification
Physical State and State: Liquid Color: Colorless to light yellow Odor: Aldehyde
Appearance
CERCLA Acrolein 0.15 gal.
Reportable Quantity
Continued on Next Page
MAGNACIDE® B MICROBIOCIDE Page: 2/11
Hazard Summary DANGER. May be highly toxic if inhaled. Flammable liquid. Can form explosive
mixtures at temperatures at or above the flash point. Vapors can flow
along surfaces to a distant ignition source and flash back. May cause skin
sensitization (allergic reaction) in sensitive individuals.
Routes of Exposure Skin (Permeator, Contact), Eyes, Inhalation.
Potential Acute Health
Effects
Eyes May be severely irritating to the eyes. Prolonged contact may cause burns.
Skin May be severely irritating to the skin. May cause burns on prolonged contact.
May cause allergic skin reactions in sensitive individuals. May be toxic if
absorbed through the skin.
Inhalation May be highly toxic if inhaled.
Ingestion Not considered a likely route of exposure; however, may be toxic if swallowed.
Medical Conditions Exposure to this product may aggravate medical conditions involving the
Aggravated by following: respiratory tract, eyes, skin/epithelium, cardiovascular system.
Exposure
See Toxicological Information (Section 11)
Additional Hazard Overexposure to vapors may be fatal. Inhalation exposure studies have
determined the rat LC50 to be 26 ppm at one hour exposure and at four hour
exposure to be 8.3 ppm. The NIOSH IDLH (Immediately Dangerous to Life and
Health) value is 2 ppm. The primary route of exposure is inhalation; acute
exposure may result in lacrimation, tracheobronchitis, pneumonia, and lung injury
(at 20 ppm). The low odor detection (0.03 � 0.21 ppm) and irritation threshold
(0.25 - 0.5 ppm) and acutely irritating effects of acrolein usually prevent chronic
toxicity effects. Splashes to the eye may result in blepharoconjunctivitis
(bloodshot eyes), lid edema, fibrinous or pustular discharge, and deep or long-
lasting corneal injury. See Section 11 for additional information.
Potential Environmental This product is very toxic to aquatic organisms.
Effects
Section 4. First Aid Measures
Eye Contact Immediately flush eyes with plenty of water for at least 15 minutes, occasionally
lifting the upper and lower eyelids. Get medical attention immediately.
Skin Contact Remove contaminated clothing and shoes immediately. Wash affected area with
soap or mild detergent and large amounts of water until no evidence of chemical
remains (approximately 15-20 minutes). Get medical attention.
Inhalation Remove to fresh air. Oxygen may be administered if breathing is difficult. If not
breathing, administer artificial respiration and seek medical attention
Ingestion If swallowed, do not induce vomiting unless directed to do so by medical
personnel. Wash out mouth with water if person is conscious. If fully conscious
promptly drink one to two glasses of water. Never induce vomiting or give
Continued on Next Page
MAGNACIDE® B MICROBIOCIDE Page: 3/11
anything by mouth to a victim who is unconscious or having convulsions. Get
medical attention immediately.
Additional First Aid Persons exposed to vapors may have a delayed reaction and experience severe
irritation of the respiratory tract and delayed pulmonary edema. Therefore, it is
strongly advised to keep person exposed to high concentrations of vapor under
observation for at least 24 hours following exposure. Measures against
circulatory shock, respiratory depression, and convulsion may be needed.
Notes to Physician Treatment of the irritative effects of acrolein should be symptomatic and
supportive. Following inhalation of acrolein, signs of respiratory dysfunction
should be sought and hypoxia corrected. Specific treatment for bronchospasm and
non-cardiogenic pulmonary edema may be necessary. Hypoxia may also occur
following the ingestion of acrolein if there is pulmonary aspiration and/or
laryngeal edema. The extent and severity of the corrosive effects on the upper
gastrointestinal mucosa should be determined, for example, by endoscopy, and
advice should be sought regarding the need for surgical intervention. Probable
mucosal damage may contraindicate the use of gastric lavage.
Section 5. Fire Fighting Measures
Flammability of the Flammable liquid. Can form explosive mixtures at temperatures at or above the
Product flash point. Vapors can flow along surfaces to a distant ignition source and flash
back.
OSHA Flammability 1B
Class
Autoignition 220°C (428°F)
temperature
Flash Point Closed cup: -25°C (-13°F) (TCC)
Flammable Limits L.E.L. 2.8% U.E.L. 31%
Products of Carbon oxides (CO, CO2), Peroxides
Combustion
Conditions to Avoid Open Flames/Sparks/Static/Heat.
Fire Fighting Media In case of fire, use foam, dry chemicals, or CO2 fire extinguishers. Evacuate area
and Instructions and fight fire from a safe distance. Water spray may be used to keep fire-exposed
containers cool. Keep water runoff out of sewers and public waterways. Note that
flammable vapors may form an ignitable mixture with air. Vapors can travel
considerable distances and flash back if ignited.
Protective Clothing Do not enter fire area without proper personal protective equipment, including
(Fire) NIOSH approved self-contained breathing apparatus.
Special Remarks on Acrolein fumes and its combustion products (carbon monoxide and peroxides) are
Fire Hazards toxic.
Continued on Next Page
MAGNACIDE® B MICROBIOCIDE Page: 4/11
Section 6. Accidental Release Measures
General Information Evacuate all personnel to an upwind area and determine medical treatment needs.
If qualified to do so through appropriate training (such as HAZWOPER) contain
or mitigate the spill as outlined below. Put on appropriate personal protective
equipment. See Section 8 for information on use of respiratory protection
appropriate for dealing with small spills. For large spills, wear fully
encapsulating, vapor protective clothing (Level A Suit) and seek assistance from
local fire department hazardous materials response team. Keep personnel
removed and upwind of spill. Shut off all ignition sources; no flares, smoking, or
flames in spill area. Approach release from upwind. Ventilate the release area.
Large Spill Vapor suppression: if available, blanket spill area with alcohol foam at 6% to
reduce the vapor concentration. Reapply foam as needed to counteract the rapid
breakdown of the foam blanket. Pump bulk fluid to appropriate storage containers
for proper disposal. After recovery of the bulk fluid, neutralization of any
remaining material can be accomplished by covering with sodium carbonate (soda
ash) and mixing with water. Ratio is 20 pounds of soda ash to each gallon of
acrolein followed by 5 gallons of water per gallon of acrolein. The soda ash and
acrolein will form a solid by-product after addition of water. When deactivation is
complete, scoop the solid material into properly marked containers for disposal.
Contain all water for proper disposal. Prevent runoff from entering drains, sewers
or waterways.
Small Spill (< 1 pound) Cover release with sodium carbonate (soda ash) and mix into spill with water.
The soda ash and acrolein will form a solid by-product after addition of water.
Alternately, absorb with paper towel, dry sand or other absorbent. For ground or
surface contamination, remove contaminated media and dispose of properly.
Contain all water for proper disposal.
Waste must be disposed of in accordance with federal, state and local
environmental control regulations.
Other Statements If RQ (Reportable Quantity) is exceeded, report to National Spill Response Office
at 1-800-424-8802.
Section 7. Handling and Storage
Handling and Storage Put on appropriate personal protective equipment. Avoid contact with eyes, skin
and clothing. Avoid breathing vapors or spray mists. Use only with adequate
ventilation. Store in a secure and well ventilated area. Keep away from heat,
sparks and flame. Keep away from incompatible materials. Keep container tightly
closed when not in use. To avoid fire or explosion, ensure containers and
equipment are properly bonded and grounded prior to transferring product. This
is normally accomplished through the use of Baker Petrolite-specified standard
application procedures. When using product under non-routine conditions (e.g.,
laboratory samples), ensure material and container are properly bonded and
Continued on Next Page
MAGNACIDE® B MICROBIOCIDE Page: 5/11
grounded.
Additional Handling and Do not reuse empty container. Return empty containers to Baker Petrolite
Corporation, 19815 South Lake Road, Taft, CA 93268.
Section 8. Exposure Controls/Personal Protection
Engineering Controls Provide exhaust ventilation or other engineering controls to keep the airborne
concentrations of vapors or mists below their respective threshold limit value.
Ensure that adequate wash water, such as eyewash stations and safety showers,
are proximal to the work location.
Personal Protection
Personal protective equipment recommendations are based on anticipated known
manufacturing and use conditions. These conditions are expected to result in only
incidental exposure. A thorough review of the job tasks and conditions by a safety
professional is recommended to determine the level of personal protective
equipment appropriate for specific job tasks and conditions.
Eyes Chemical safety goggles.
Body Long sleeved shirts and work pants.
Respiratory Full-face respirator use is required when connecting or disconnecting containers
to application equipment, or any situations where the permissible exposure limit
may be exceeded. As per NIOSH, full-face air-purifying respirators may be worn
to protect personnel up to 2 ppm (IDLH) acrolein. The air purifying respirators
should have organic vapor cartridge(s) or canister and a protection factor of 50.
Exposure levels of unknown concentrations or greater than 2 ppm acrolein require
the use of full- face positive pressure supplied-air breathing apparatus with a
protection factor of 10,000.
Hands Butyl rubber gloves; replace as needed.
Feet Boots or shoes.
Section 9. Typical Physical and Chemical Properties
Physical State and Liquid. Odor Aldehyde
Appearance
pH 6 max. (10% in water) Color Colorless to light yellow.
Specific gravity 0.847 @ 16°C (60°F)
Density 7.06 lbs/gal @ 16°C (60°F)
Vapor Density 1.94 (Air = 1)
Vapor Pressure 234.9 mmHg @ 22ºC
Evaporation Rate >1 (compared to Ether (anhydrous)).
VOC > 95%
Continued on Next Page
MAGNACIDE® B MICROBIOCIDE Page: 6/11
Viscosity 0.329 cps @ 20°C (68°F)
Pour Point -86.7°C (-124°F)
Solubility (Water) Soluble (22% by weight @ 20°C)
Boiling Point 53°C (127°F) @ 760 mm Hg
Section 10. Stability and Reactivity
Stability and Reactivity The product is stable under normal use and storage conditions..
Conditions of Instability This product is stable unless there is a loss of stabilizer.
Incompatibility with Alkalies, amines, light, and oxidizing materials. Alkaline or strong acid
Various Substances contamination can cause a reaction which can be rapid and violent. Prevent water
contamination of acrolein storage containers.
Hazardous Carbon oxides (CO, CO2), Peroxides.
Decomposition
Products
Hazardous Hazardous polymerization may occur.
Polymerization
Special Stability & Loss of hydroquinone stabilizer may result in polymerization under certain
Reactivity Remarks conditions. Air introduced into closed containers may cause a slow
polymerization, resulting in loss of product quality.
Section 11. Toxicological Information
Product Toxicological Information
Acute Animal Toxicity
Oral (LD50): 29 mg/kg [Rat]; 11.8 mg/kg [Female rat]; 10.3 mg/kg [Male rat].
Dermal (LD50): 231.4 mg/kg [Rabbit].
Vapor (LC50): 26 ppm at 1 hour [Rat], 8.3 ppm at 4 hours [Rat]
Irritation - Draize Test (Rabbit)
Skin � 0.1 ml/24H: Severe
Eye � 0.5 ml/24H: Severe
Skin � 0.5 ml of 15 ppm solution/24H: Not irritating
Toxicity Data
1) Acrolein
A potential human health effect resulting from overexposure is the development of permanent lung damage in
the form of decreased pulmonary (lung) function, and delayed pulmonary edema (fluid in the lungs) which can
lead to chronic respiratory disease. As a highly reactive aldehyde, prolonged or repeated overexposures can
produce long-term respiratory effects by significantly reducing ciliary action in the upper airways (i.e.,
interfering with the body’s ability to clear mucous and foreign substances from the respiratory tract) and
causing
Continued on Next Page
MAGNACIDE® B MICROBIOCIDE Page: 7/11
tissue damage throughout the lungs manifested as emphysema.
Acrolein levels of 0.4 to 4.9 ppm caused eye and nose irritation and structural changes in the respiratory system
of hamsters, rats and rabbits (Ref. 1). Acrolein produced greater susceptibility to respiratory infections in mice
(Ref. 2) and rats (Ref. 3).
Developmental/Reproduction studies
Acrolein has been tested for developmental and reproductive health effects. Results from developmental studies
(Ref. 4, 5) indicated this material did not cause teratogenic effects in rats or rabbits at doses that caused
maternal toxicity. A two-generation rat reproductive study (Ref. 6) did not reveal any evidence of reproductive
toxicity in either sex from any treatment group (maximum dose = 7.2 mg/kg). A second two-generation
reproductive study in rats did not reveal any evidence of reproductive toxicity in either sex from any treatment
group (maximum dose = 6 mg/kg) (Ref. 6).
Dermal Testing
In a 21 day dermal toxicity test in rabbits dosed at 7, 21 and 63 mg/kg of acrolein, toxicity was evidenced by
slight to significant reduction in body weight gain, nasal mucous discharge, lethargy, slight to moderately
lowered food consumption and increased frequency of lesions of the skin and lungs. Slight mortality in female
rabbits dosed at 21 and 63 mg/kg was observed. No notable effects in hematology, blood chemistry, organ
weights or organ weight ratios were observed (Ref. 7).
Inhalation toxicity study
Rats were exposed by inhalation (6h/day 5 d/week for 62 days) to 0, 0.4, 1.4 and 4.0 ppm acrolein. Mortality
was only observed in the 4 ppm group and was due mainly to acute bronchopneumonia. Weight gain in the 4
ppm group was significantly slower than the control group. Examination of the 4 ppm group revealed
bronchiolar epithelial necrosis and sloughing and edema (Ref. 8).
Chronic toxicity/Oncogenicity studies
In a 12-month chronic toxicity test in dogs (Ref. 9), the highest dose (2 mg/kg) tested resulted in changes in
blood chemistry, but no compound-related tumors or lesions were observed. An 18-month oncogenicity study in
mice (Ref. 10) did not reveal any compound-related tumors or lesions; the highest dose tested (4.5 mg/kg)
resulted in increased mortality in the test group. A 24-month chronic toxicity/oncogenicity study in rats (Ref.
11) also did not reveal any compound related tumors or lesions. The high dose, 2.5 mg/kg, caused an increased
mortality in the test group. No indications of cancer were found in the tests.
Other Studies
Mutagenicity studies
Effects of Acrolein on the In Vitro Induction of Chromosomal Aberrations in CHO Cells: No significant
increase in the number of chromosomal aberrations above the background (Ref. 12).
Continued on Next Page
MAGNACIDE® B MICROBIOCIDE Page: 8/11
Effects of Acrolein on the In Vivo Induction of Chromosomal Aberrations in Rat Bone Marrow Cells: No
significant increase in the number of chromosomal aberrations above the background (Ref. 13).
Salmonella Liquid Suspension Mutant Fraction Assay: Acrolein did not induce concentration-dependent
mutagencity in any of the 5 Salmonella strains, either in the presence or absence of metabolic activation (Ref.
14).
Metabolism Data
Metabolism studies in freshwater fish, shellfish, goats, hens, rats and leaf lettuce indicate that acrolein is
metabolized and does not accumulate in the tissue (Ref. 15-19).
Target Organs respiratory tract, eyes, skin/epithelium, cardiovascular system.
Section 12. Ecological Information
Ecotoxicity This product is very toxic to aquatic organisms.
Bluegill sunfish (Lepomis macrochirus) 96H LC50: 24 ppb
Rainbow trout (Oncorhynchus mykiss) 96H LC50: 24 ppb
Water flea (Daphnia magna) 48H LC50: 22 ppb
Eastern oysters (Crassostrea virginica) 96H EC50: 180 ppb
Mysid shrimp (Mysidopsis bahia) 96H LC50: 500 ppb
Mysid shrimp (Holmesimysis costata) 96H LC50: 790 ppb
Sheepshead minnows (Cyprinodon variegatus) 96H LC50: 570 ppb
Marine copepod (Acartia tonsa) 48H LC50: 55 ppb
Saltwater diatom (Skeletonema costatum) 120H EC50: 27 ppb
BOD5 and COD Not available.
Biodegradation In an aerobic aquatic metabolism study, the water phase revealed the rapid
degradation of acrolein with all metabolites further mineralized to carbon
dioxide. Results indicate hydration was an early step in acrolein degradation. The
first- order kinetic half-life of acrolein was determined to be 33.7 hours in the
water phase under laboratory conditions. Under field conditions, the half-life of
acrolein in freshwater ranged from six to ten hours (Ref. 20).
In an aerobic soil metabolism study the half-life of acrolein was found to be 4.2
hours in soil-water mixtures and was ultimately transformed into carbon dioxide
(Ref. 21).
Special Remarks None.
Section 13. Disposal Considerations
Responsibility for proper waste disposal rests with the generator of the waste. Dispose of any waste material in
accordance with all applicable federal, state and local regulations. Note that these regulations may also apply to
empty containers, liners and rinsate. Processing, use, dilution or contamination of this product may cause its
physical and chemical properties to change.
Continued on Next Page
MAGNACIDE® B MICROBIOCIDE Page: 9/11
Do not clean or reuse empty container. Return empty containers to Baker Petrolite Corporation, 19815 South
Lake Road, Taft, CA 93268.
Additional Waste EPA Waste Code for acrolein is:
Remarks Waste Acrolein, stabilized
Waste Code � P003
Section 14. Transport Information
DOT Classification Acrolein, stabilized, 6.1(3), UN1092, I
Toxic-Inhalation Hazard, Zone A, RQ,
Marine Pollutant
DOT Reportable Acrolein 0.15 gal.
Quantity
Marine Pollutant Acrolein
Additional DOT DOT SP 10705 (DOT SP 10705 applies only to mixed loads)
Information DOT SP-14341 (DOT SP-14341 applies only to 4BW welded cylinders.)
Emergency Response 131P
Guide Page Number
Section 15. Regulatory Information
HCS Classification Target organ effects. Flammable liquid. Toxic.
U.S. Federal
Regulations
Environmental Extremely Hazardous Substances: Acrolein
Regulations SARA 313 Toxic Chemical Notification and Release Reporting: Acrolein
SARA 302/304 Emergency Planning and Notification substances: Acrolein
Hazardous Substances (CERCLA 302): Acrolein: 0.15 gal.
SARA 311/312 MSDS distribution � chemical inventory � hazard identification:
fire; reactive; immediate health hazard
Clean Water Act (CWA) 307 Priority Pollutants: Acrolein
Clean Water Act (CWA) 311 Hazardous Substances: Acrolein
Clean Air Act (CAA) 112( r ) Accidental Release Prevention Substances:
Acrolein
Threshhold Acrolein: 74 gal.
Planning
Quantity (TPQ)
TSCA Inventory All components are included on or are exempted from listing on the US Toxic
Status Substances Control Act Inventory.
This product does not contain any components that are subject to the reporting
requirements of TSCA Section 12(b) if exported from the United States.
Continued on Next Page
MAGNACIDE® B MICROBIOCIDE Page: 10/11
State Regulations State specific information is available upon request.
International
Regulations
Canada All components are compliant with or are exempted from listing on the Canadian
Domestic Substances List.
WHMIS B-2, D-1A, E
European Union All components are included or are exempted from listing on the European
Inventory of Existing Commercial Chemical Substances or the European List of
Notified Chemical Substances.
Additional international inventory status information is available upon request.
Section 16. Other Information
References:
1. Feron, J.V. et al.; Toxicology 9 (1-2): 47-58 (1978).
2. Jakab, G.J.; Am Rev Resp Dis 1977 155:33-38.
3. Bouley, G.: Eur J Toxicol Eur Environ Hyg 1975: 8:291-297.
4. Parent, R.A., Caravello, H.E., Christian, M.S., and Hoberman, A.M.. Developmental Toxicity of Acrolein in
New Zealand White Rabbits. Fundamental and Applied Toxicology. 20, 248-256 (1993).
5. Teratolgy Study of Acrolein in Rats, Bioassay Systems Corporation, Woburn, MA (1982) (Unpublished
Study).
6. Parent, R.A., Caravello. H.E., and Hoberman, A.M.. Reproductive Study of Acrolein on Two Generations of
Rats. Fundamental and Applied Toxicology. 19:228-237 (1992).
7. 21 Day Dermal Test of Acrolein in Rabbits, Bioassay Systems Corporation, Woburn, MA, 1982
(Unpublished Study).
8. A Sub-Chronic Inhalation Study of Fischer 344 Rats Exposed to 0, 0.4, 1.4, or 4.0 ppm Acrolein.
Brookhaven National Laboratory, Upton, NY, 1981.
9. Parent, R.A., Caravello, H.E., Balmer, M.F., Shellenberger, T.E., and J.E. Long, One Year Chronic Toxicity
of Orally Administered Acrolein to Beagle Dogs. J. Appl. Tox. 12(0): 1-9 (1992).
10. Parent, R.A., Caravello, H.E., and Long, J.E.. Oncogenicity Study of Acrolein in Mice. Journal of the
American College of Toxicology. 10(6), 647-659 (1991).
11. Parent, R.A., Caravello, H.E. and Long, J.E.. Two-year Toxicity and Carcinogenicity Study of Acrolein in
Rats. Journal of Applied Toxicology, Vol. 12(2), 131-139 (1992).
12. Effects of Acrolein on the In Vitro Induction of Chromosomal Aberrations in CHO Cells, Bioassay
Systems, Woburn, MA, 1982 (Unpublished Study).
13. Effects of Acrolein on the In Vivo Induction of Chromosomal Aberrations in Rat Bone Marrow Cells,
Bioassay Systems, Woburn, MA, 1982 (Unpublished Study).
14. Salmonella Liquid Suspension Mutant Fraction Assay, Bioassay Systems, Woburn, MA, 1980 (Unpublished
Study).
15. Nordone, A.J., Dotson, T.A., Kovacs, M.F., Doane, R.A., and Biever, R.C.. Metabolism of [14C]Acrolein
(MAGNACIDE® H Herbicide): Nature and Magnitude of Residues Using Freshwater Fish and Shellfish.
Continued on Next Page
MAGNACIDE® B MICROBIOCIDE Page: 11/11
Environ. Toxicol. And Chemistry. 17(2): 276-281 (1998).
16. Nordone, A.J., Dotson, T.A., Kovacs, and Doane, R.A.. [14C] Acrolein: Accumulation and Metabolism in
Leaf Lettuce. Bull. Environ. Contam. Toxicol. (58):787-792 (1997).
17. Sharp, D.E., Berge, M.A., Paust, D.E., Talaat, R.E., Wilkes, L.C., Servatius, L.J., Loftus, M.L., Caravello,
H.E., and Parent, R.A.. Metabolism and Distribution of [2,3-14C]Acrolein in Lactating Goats. J. of Agric. and
Food Chem. 49(3): 1630-1638 (2001).
18. Sharp, D.E., Berge, M.A., Hennes, M.G., Wilkes, L.C., Servatius, L.J., Loftus, M.L., Caravello, H.E., and
Parent, R.A.. Metabolism and Distribution of [2,3-14C]Acrolein in Laying Hens. J. of Agric. and Food Chem.
49(3): 1639-1647 (2001).
19. Parent, R.A., Caravello, H.E., and Sharp, D.E.. Metabolism and Distribution of [2,3-14C]Acrolein in
Sprague-Dawley rats. Journal of Applied Toxicology, Vol 16(5), 449-457 (1994).
20. Smith, A.M., Mao, J., Doane, R.A., and Kovacs, M.F.. Metabolic Fate of [14C]Acrolein Under Aerobic and
Anaerobic Aquatic Conditions. J. of Agric. and Food Chem. 43(9): 2497-2503 (1995).
21. Estimation of the Aerobic Biotransformation Rates of Acrolein (MAGNACIDE® H Herbicide,
MAGNACIDE® B Biocide) in Soil, SRI International, Menlo Park, CA, (1990) (Unpublished Study).
10/07/02 - Update to Section 3
10/31/02 - Update to Section 14
11/06/02 - Update to sections 5, 8, 14, and 15 (Canada)
04/29/03 - Update to Section 2
05/05/03 - Update to Section 7
12/30/03 - Changes to Sections 2, 3, 8, 10, and 11.
05/18/04 � Changes to Sections 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16.
01/25/05 � Changes to Sections 3 and 11.
01/08/07 � Change to Section 14.
Baker Petrolite Disclaimer
NOTE: The information on this MSDS is based on data which is considered to be accurate. Baker Petrolite,
however, makes no guarantees or warranty, either expressed or implied of the accuracy or completeness of this
information.
The conditions or methods of handling, storage, use and disposal of the product are beyond our control and
may be beyond our knowledge. For this and other reasons, we do not assume responsibility and expressly
disclaim liability for loss, damage or expense arising out of or in any way connected with the handling, storage,
use or disposal of this product.
This MSDS was prepared and is to be used for this product. If the product is used as a component in another
product, this MSDS information may not be applicable.
|